Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.475 USD | -1.81% | -0.57% | -43.84% |
05-14 | Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression | MT |
05-14 | Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.84% | 1.54B | |
+64.04% | 62.59B | |
-2.04% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+12.45% | 26.21B | |
-21.98% | 19.09B | |
+3.68% | 13.08B | |
+25.57% | 12.26B | |
+27.19% | 12.05B |
- Stock Market
- Equities
- NMRA Stock
- News Neumora Therapeutics, Inc.
- Neumora Therapeutics Q4 Loss Narrows